Women are at higher risk of developing venous thromboembolism (VTE) when using the Ortho Evra Contraceptive Transdermal Patch, according to a new label approved by the U.S. Food and Drug Administration (FDA) on Friday.
VTE can lead to pulmonary embolism, the FDA said.
The prescription patch releases ethinyl estradiol (an estrogen hormone) and norelgestromin (a progestin hormone) through the skin into the blood stream
